Many firsts as deadlines draw closer, yet bottleneck concerns remain
Less than one year remains before the European Union’s new Medical Device Regulation (MDR) goes into effect on May 26, 2020, and only about a fourth of medical device companies plan to be fully complaint, according to a report by the Regulatory Affairs Professionals Society and KPMG. One of the major challenges to reaching full compliance by the deadline are notified body (NB) capacity shortages.
While Vytenis Andriukaitis, the European Commissioner for Health and Food Safety, expects around 20 NBs to be designated before the end of 2019, there remains a great deal of uncertainty about whether companies will be able to find a NB to certify their devices. Only five NBs are currently certified to review devices under the new MDR regulation, and designation of NBs has lagged overall, with several exiting the sector.
Moreover, until recently, no NBs had been designated under the new In Vitro Diagnostic Regulation (IVDR), creating a barricade to any in vitro diagnostics (IVDs) entering the EU market under the new rules. Now, with only one designated NB (see below), the capacity to assess IVDs under IVDR may be inadequate to meet the demand before the May 2022 deadline, creating bottlenecks that could result in product shortages. Below, we summarise recent updates.
New NB designations under MDR
TÜV Rheinland became the fifth notified body designated under MDR, after Instituto Italiano del Marchio di Qualita S.P.A. (IMQ), BSI Assurance UK Ltd, TÜV SÜD Product Service GmbH and DEKRA Certification GmbH. Further, not all of these NBs are designated to certify all device classifications, therefore, more designations are needed to ensure adequate NB availability and European market access for manufacturers.
First two NBs designated under IVDR
In October, DEKRA became the first NB designated for the IVDR, shortly followed by BSI. The UK-based NB stated it is the first NB to achieve full scope designation, which covers all devices for IVDR, including new categories of devices that were not covered by previous directives such as genetic tests and companion diagnostics.
Until recently, the lack of NBs designated to review IVDs caused a complete roadblock to marketing these products under the new regulation. Under the existing directives, most IVDs could self-certified, with less than seven percent of IVDs requiring NB certification. That number is projected to increase to nearly 85 percent under IVDR. Currently, there are nine additional NBs in the process of designation, although doubts still remain whether all IVDs on the EU market will be able to obtain certification by the May 2022 deadline.
First device certified under EU MDR
The Novartis Concept1 inhaler became the first certified product under MDR through BSI, in September. Previously, the inhaler was classified as a Class I device, and did not require review by an NB. It is now classified as a Class IIa device. This is one example of hundreds of devices that will need to undergo NB review under MDR, adding to growing backlog of submissions.
New EU regulations call for UDI numbers
An important aspect of the new regulations is the creation of an identification system based on unique device identifiers (UDIs) to improve product traceability, reduce medical errors and facilitate accurate reporting of adverse events. Earlier this summer, the European Commission designated four supply chain standard organisations as issuing entities for UDIs: GS1, Health Industry Business Communications Council (HIBCC), International Council for Commonality in Blood Banking Automation (ICCBBA), and Informationsstelle für Arzneispezialitäten. The new rules require that a UDI number be applied to the medical device label, packaging or device itself. In addition, product data must be submitted to European Database on Medical Devices (Eudamed) to help enforce the safety and performance requirements of the regulations.
Classifying software under MDR, IVDR
The European Commission’s Medical Device Coordination Group (MDCG) released guidance to help medical software manufacturers understand necessary criteria for the qualification of software under the MDR and IVDR. The guidance details examples of software that would be classified under MDR or IVDR, including software that can control, operate, or modify the state of a medical device, provide immediate decision-triggering information, or provide support for health professionals.
Eudamed delayed until 2022
European Commission officials confirmed plans to delay the implementation of Eudamed, pushing the date from March 2020 to May 2022 which coincides with the implementation date for the In Vitro Diagnostic Regulation, set to take effect May 26, 2022.
Next steps
To ensure compliance under MDR and IVDR before rapidly approaching deadlines, manufacturers should act quickly to identify and secure a NB. Manufacturers should evaluate expertise and resources to determine which NBs are the best fit for their products. Additionally, manufacturers should expect a queue for NB review of clinical evidence and, therefore, should plan to engage with NBs early to discuss timelines to avoid bottlenecks and delays. Moving forward, manufacturers may benefit from the expertise of a strategic partner that can provide support in navigating increasingly complex regulatory landscapes.
For more information, download our white paper or contact ICON’s Medical Device and Diagnostics Research regulatory team.
In this section
-
Digital Disruption
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
- Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Therapeutic spotlight: Precision medicine considerations in rare diseases
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Flexible delivery models
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel